Toshiyuki Sakai

机构：Toyo University, Kyoto Prefectural University of Medicine · ORCID：0000-0002-7865-2258

发表论文 506 篇 · 总被引 14907 次 · h-index 64

代表论文

• Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer (2024 · Cancer Letters · 被引 20)
• AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells (2024 · Cancer Letters · 被引 18)
• Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer (2024 · British Journal of Cancer · 被引 14)
• Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer (2025 · Molecular Cancer Therapeutics · 被引 8)
• YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers (2024 · Clinical Cancer Research · 被引 8)
• Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells (2024 · Cancer Science · 被引 4)